Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

Phase 4 Completed 34 enrolled Ruhr University of Bochum Heart and Diabetes Center North-Rhine Westfalia · collab Solvay Pharmaceuticals · collab

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to determine whether a 6-week treatment with 4 g Omacor/day improves the baseline and postprandial endothelial function (after a high-fat meal) in patients with type 2 diabetes mellitus.

Timeline

Start: 2007-04
Primary completion: 2008-11
Completion: 2008-11

Publications

Stirban A, Nandrean S, Gotting C, Stratmann B, Tschoepe D. Effects of n-3 polyunsaturated fatty acids (PUFAs) on circulating adiponectin and leptin in subjects with type 2 diabetes mellitus. Horm Metab Res. 2014 Jun;46(7):490-2. doi: 10.1055/s-0033-1363225. Epub 2013 Dec 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lovaza	Other / unclassified	4 g	—

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Publications

Drugs

Indications